Show simple item record

dc.contributor.advisorNoubar Afeyan and Roy Welsch.en_US
dc.contributor.authorHunnicutt, Leigh Anneen_US
dc.contributor.otherLeaders for Manufacturing Program.en_US
dc.date.accessioned2008-12-11T18:35:57Z
dc.date.available2008-12-11T18:35:57Z
dc.date.copyright2008en_US
dc.date.issued2008en_US
dc.identifier.urihttp://hdl.handle.net/1721.1/43837
dc.descriptionThesis (M.B.A.)--Massachusetts Institute of Technology, Sloan School of Management; and, (S.M.)--Massachusetts Institute of Technology, Biological Engineering Division; in conjunction with the Leaders for Manufacturing Program at MIT, 2008.en_US
dc.descriptionMIT Institute Archives copy: pages, 85-86, 87-88, 89-90 bound in reverse order.en_US
dc.descriptionIncludes bibliographical references (p. 79-83).en_US
dc.description.abstractThe biopharmaceutical industry uses recombinant protein technologies to provide novel therapeutics to patients around the world. These technologies have presented exciting opportunities for breakthrough medical treatments while creating a host of challenges in the discovery, development and manufacture of these products. Protein aggregation is one of the challenges currently limiting the ability to bring new biopharmaceutical products into the market and to manufacture existing commercial products. The mechanisms of aggregation and subsequent particle formation are highly complex, incompletely understood, and difficult to measure quantitatively with currently available analytical tools. Aggregates, and their effect on product appearance, may compromise value to the patient (bioavailability, dose, therapeutic activity and immunogenicity) as well as value to the company (yield loss and performance in a competitive marketplace) and are therefore tightly regulated. This thesis is intended to explore the problem of protein particles through two main avenues: meeting current regulatory criteria and influencing future regulation. Process changes, analytical characterization, and organizational improvements are each addressed to achieve that goal. An experiment was designed and completed to jointly examine (1) changes to manufacturing processes using novel filtration applications intended to reduce or remove protein particles from solution and (2) analytical tools for improved characterization. Organizational dynamics and resource allocation add an extra layer of complexity and are discussed in relation to leveraging knowledge regarding particles.en_US
dc.description.abstract(cont.) Additionally, three objectives are established to influence the direction of future regulation: the need for improved characterization, industry collaboration and a healthy interface with regulatory bodies.en_US
dc.description.statementofresponsibilityby Leigh Anne Hunnicutt.en_US
dc.format.extent90 p.en_US
dc.language.isoengen_US
dc.publisherMassachusetts Institute of Technologyen_US
dc.rightsMIT theses may be protected by copyright. Please reuse MIT thesis content according to the MIT Libraries Permissions Policy, which is available through the URL provided.en_US
dc.rights.urihttp://dspace.mit.edu/handle/1721.1/7582en_US
dc.subjectSloan School of Management.en_US
dc.subjectBiological Engineering Division.en_US
dc.subjectLeaders for Manufacturing Program.en_US
dc.titleInvestigating late stage biopharmaceutical product loss using novel analytical and process technologyen_US
dc.typeThesisen_US
dc.description.degreeS.M.en_US
dc.description.degreeM.B.A.en_US
dc.contributor.departmentLeaders for Manufacturing Program at MITen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biological Engineering
dc.contributor.departmentSloan School of Management
dc.identifier.oclc262697848en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record